Format

Send to

Choose Destination
Clin Cancer Res. 2013 Aug 15;19(16):4326-34. doi: 10.1158/1078-0432.CCR-13-0779. Epub 2013 Jun 14.

BRAF in melanoma: current strategies and future directions.

Author information

1
Division of Medical Oncology, Duke University Medical Center, Durham North Carolina, USA.

Abstract

Selective BRAF inhibitors have now been established as a standard of care option for patients diagnosed with metastatic melanoma whose tumors carry a BRAF mutation. Their successful development represents a milestone in the treatment of this disease, and has the potential to impact therapy for other malignancies as well. The use of these agents, however, has introduced a number of critical questions about the optimal use and selection of patients for BRAF inhibitor therapy. This review discusses the current status of BRAF inhibitor clinical development, the clinicopathologic features of BRAF-mutated melanoma, as well as strategies for overcoming resistance.

PMID:
23770823
DOI:
10.1158/1078-0432.CCR-13-0779
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center